Arcturus rallies after Japan COVID booster data published in article

Shares of Arcturus Therapeutics are moving higher after the disclosed that an article titled “Booster dose of self-amplifying SARS-CoV-2 RNA vaccine vs. mRNA vaccine: a phase 3 comparison of ARCT-154 with Comirnaty” was posted on medRxiv.org. The article is based on interim results of a Phase 3 study conducted in Japan by Meiji Seika Pharma evaluating the safety and immunogenicity of ARCT-154 compared to Comirnaty as a booster against COVID-19. The article is a preprint and has not yet been certified by peer review. As previously announced, Meiji entered into a distribution agreement with Seqirus for the distribution and sales of ARCT-154, Arcturus Therapeutics’ self-amplifying mRNA vaccine candidate against COVID-19, in Japan. Shares of Arcturus are up 13% to $34.76.